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Hepatic hydrothoraxAbstract Background: Hepatic hydrothorax treatment remains problematic, and chemical pleu-
rodesis can be considered.
Objectives: The aim of this study is to compare the efﬁcacy and safety of chemical pleurodesis by
small bore catheter to tube drainage in hepatic hydrothorax.
Methods: A randomized clinical study included 30 patients with hepatic hydrothorax who were
admitted to Chest Department, Mansoura University Hospital, Egypt from 2011 to 2014. Patients
diagnosed with exudative effusion, renal impairment, hepatic encephalopathy were excluded.
Patients were divided into 2 groups; group A (20 patients) managed by small catheter and group
B (10 patients) managed by intercostal tube, chemical pleurodesis in both groups was done by Vis-
cum. Clinical, radiological data and hospital stay duration were adopted for comparison between
both groups.
Results: Pleurodesis was successful in group A 65% (13 patients) and in group B 70%
(7 patients). Hospital stay duration was 10 days for group A and 11 days for group B. Post
procedure chest pain score was less in group A than group B which was statistically signiﬁcant.
No serious complications and no mortality occured.
Conclusions: Small bore catheter chemical pleurodesis has successful outcome, less post proce-
dure chest pain and minimal complications in refractory hepatic hydrothorax.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatic hydrothorax is deﬁned as pleural effusion (greater
than 500 mL) in cirrhotic patients with no primary cardiacor pulmonary diseases [1,2]. It is a manifestation of decompen-
sated chronic liver disease, similar to the presence of ascites,
hepatic encephalopathy, or variceal hemorrhage, the most
likely mechanism is the passage of ascetic ﬂuid from the peri-
toneal to the pleural cavity through diaphragmatic defects usu-
ally less than 1 cm, located in the tendinous portion of the
diaphragm [3].
Hepatic hydrothorax is mostly right-sided (up to 85%) and
is associated with ascites, initial treatment entails pleural spacerculosis.
Table 1 The McGill Pain Questionnaire [8].
0 None
1 Mild, requiring no medications
2 Discomforting, requiring mild analgesics
3 Distressing, requiring strong analgesics
4 Horrible, requiring narcotic analgesics
5 Excruciating, not responding to narcotic analgesics
188 A.A. Hewidy et al.drainage by thoracentesis for diagnostic evaluation and for
therapeutic beneﬁt. A sodium-restricted diet and judicious
use of a loop diuretic with an aldosterone receptor antagonist
(spironolactone, 100 mg/day) may provide initial ascites reduc-
tion and prevent hepatic hydrothorax development [4].
The usual treatment of hepatic hydrothorax in patients who
fail to respond to aggressive medical management of ascites
remains problematic and controversial. A review of the litera-
ture has revealed that no method is ideal at present [5]. This
study is to compare the efﬁcacy and safety of small bore cathe-
ter chemical pleurodesis and the conventional chemical pleu-
rodesis by intercostal tube drainage.
Study design
This prospective randomized controlled trial looked at two
arms of treatment of refractory hepatic hydrothorax with
chemical pleurodesis by small bore catheter (group A) and
large bore catheter (group B). Clinical, radiological data and
hospital stay duration were adopted for comparison between
both groups. The patients were randomly selected using the
closed envelop method.
Patients and methods
This study included 30 patients with hepatic hydrothorax who
were admitted to the Chest Department, Mansoura University
Hospital, Egypt from January 2011 to August 2014. Ethical
approval had been obtained from the local ethics committee.
Patients signed their written consents after detailed explana-
tion of the study protocol. Patients who had liver cirrhosis,
portal hypertension, ascites and refractory hepatic hydrotho-
rax were included in our study. In this study all patients had
failed medical treatment with multiple medical managements
in the form of sodium and ﬂuid restriction, human albumin,
diuretic therapy and repeated therapeutic thoracocentesis.
Patients who were diagnosed with exudative effusion, tubercu-
losis, bronchial carcinoma, malignant effusion, renal impair-
ment, and hepatic encephalopathy were excluded from the
study.
Full laboratory work up was done, abdominal and trans-
thoracic ultrasound chest to detect loculations and localization
for the best site of drainage. Plain chest X-ray and CT chest
scan were done before and after intervention. Aspiration of
both pleural ﬂuid and ascitic ﬂuid was done and sent for bio-
chemical analysis including pH, LDH, protein content and cel-
lular pattern and also cytolopathological examination, ZN
stain, Gram stain and culture were done for aerobic and anaer-
obic organisms.
Patients were randomly divided into two groups; group A
(20 patients) managed by small catheter insertion and group
B (10 patients) managed by intercostal tube insertion. Chemi-
cal pleurodesis in both groups was done by using Viscum (Vis-
cum Fraxini 2; ABNOBA Helmittel Gmbh-Germany) 5
ampoules diluted in 100 ml glucose 5%.
In group A, small bore catheter (Angiocath 12 gauge, Lena-
cath, Haidylena Co., 6th October, Egypt) was inserted in the
pleural cavity under trans-thoracic ultrasound guidance, and
under local anesthesia, pleural ﬂuid drainage of 1.2–1.5 L per
day was done till complete evacuation. The catheter was left
until ﬂuid drainage became less than 100 ml/day. Aftercomplete lung expansion the pleurodesis agent was injected.
The valve of catheter was closed for 2 h with rotation of
patient in all directions. Then catheter was opened to evacuate
the remaining ﬂuid. The catheter was removed after complete
lung expansion.
In group B, intercostal tube (28F) was inserted in the pleu-
ral cavity under trans-thoracic ultrasound guidance, and under
local anesthesia, pleural ﬂuid drainage of 1.2–1.5 L per day
was done until ﬂuid drainage became less than 100 ml/day.
After complete lung expansion the pleurodesis agent was then
applied to the pleural surface and recesses. The tube was closed
for 2 h then opened to remove the remaining ﬂuid and was
removed after complete lung expansion.
Successful pleurodesis was deﬁned by a patient who no
longer had dyspnea symptoms and had a chest roentgenogram
that did not show pleural effusion 1 month after the chemical
pleurodesis [6]. Dyspnea was evaluated according to American
Thoracic Society (1999) before and after the intervention [7].
Post procedure chest pain scoring was done according to
The McGill Pain Questionnaire [8] (see Table 1).
Clinical, laboratory, radiological and hospital stay duration
end points were adopted for comparing the two interventions.
Statistical methods
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 15. Qualitative data were presented as num-
ber and percent. Comparison between groups was done by
Chi-Square test. Quantitative data were presented as mean
± S.D. Student t-test was used to compare between two
groups. P< 0.05 was considered to be statistically signiﬁcant.
Results
This study included 30 patients (19 male and 11 female) with
hepatic hydrothorax who were randomly divided into two
groups, group A treated by small bore catheter pleurodesis
and group B treated by large bore catheter pleurodesis. Both
groups were compared according to the clinical, radiological
and hospital stay duration endpoints.
The mean age for group A was 54.55 ± 5.81 and the mean
age for group B was 49.40 ± 6.87. Group A included 20
patients, 13 male (65%) and 7 female (35%) while group B
included 10 patients, 6 male (60%) and 4 female (40%). In
group A, 8 patients (40%) were smokers, 8 patients (40%)
were non-smokers and 4 patients (20%) were ex-smokers. In
group B, 3 patients (30%) were smokers, 2 patients (20%) were
non-smokers and 5 patients (50%) were ex-smokers (Table 2).
Dyspnea was present in all patients of both groups, chest
pain was present in 2 patients of each group, productive cough
was present in 11 patients (55%) of group A and in 4 patients






No. % No. %
Dyspnea 20 100 20 100 – –
Dry cough 9 45 6 60 0.600 0.439
Productive cough 11 55 4 40 0.600 0.439
Chest pain 2 10 2 20 0.577 0.448
Hemoptysis 3 15 0 00 1.667 0.197
Fever 1 5 0 00 0.517 0.472














Dyspnea 20 0 <0.001* 10 1 0.003*
Dry cough 9 0 0.003* 6 3 0.083
Prod.
cough
11 2 0.003* 4 3 0.317
Chest pain 2 0 0.157 2 0 0.157
Hemoptysis 3 0 0.083 0 1 0.317
Fever 1 0 0.317 0 1 0.317






No. % No. %
Success 13 65 7 70 7.025 0.008*
Recurrent 7 35 3 30






Hospital stay 10.05 ± 2.48 11.70 ± 2.36 1.744 0.092
Table 7 Post procedure chest pain score.





No. % No. %
0 5 25 1 10 8.681 0.034
1 13 65 3 30
2 1 5 4 40
3 1 5 2 20
4 0 0 0 0
5 0 0 0 0
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of group A and in 6 patients (60%) of group B and hemoptysis
was present in 3 patients (15%) of group A.
In group A 17 patients (85%) had clear ﬂuid, 3 patients
(15%) had yellowish ﬂuid, in group B 7 patients (70%) had
clear ﬂuid, 3 patients (30%) had yellowish ﬂuid of both ascetic
ﬂuid and pleural effusion gross picture examination. Direct
Gram stain of ascetic ﬂuid and pleural effusion in both groups
showed no organisms, and ZN stain for all patients was nega-
tive (Table 3).
There was no signiﬁcant difference between biochemical
analysis of both ascetic ﬂuid and pleural ﬂuid (Table 4).
There was statistically signiﬁcant difference in group A in
improvement of dyspnea, dry cough and productive cough
after pleurodesis and in group B there was statistically signiﬁ-
cant difference in group B in improvement of dyspnea after
pleurodesis (Table 5).
In group A, 13 patients (65%) had successful pleurodesis
and 7 patients (35%) had recurrent effusion after 1 month,
in group B 7 patients (70%) had successful pleurodesis and 3
patients (30%) had recurrent effusion after 1 month (Table 6).
The duration of hospital stay was 10.05 ± 2.48 days in
group A and 11.70 ± 2.36 days in group B which was not sta-
tistically signiﬁcant (Table 7).
Post procedure chest pain score showed that in group A 5
patients (25%) had no chest pain, 13 patients (65%) had mild
pain and did not need any analgesia, one patient had discom-
forting pain that improved with mild analgesia paracetamol
500 mg tablet and one patient had distressing pain and needed
strong analgesia (Ketorolac injection). In group B one patients
(10%) had no chest pain, 3 patients (30%) had mild pain and
did not need any analgesia, 4 patient (40%) had discomforting
pain that improved with mild analgesia paracetamol 500 mg
tablet and 2 patients had distressing pain and needed strong
analgesia (Ketorolac injection). Post procedure chest pain
score was less in group A than in group B which was statisti-




Pleural eﬀusion Ascetic ﬂuid
pH 7.62 ± 0.40 7.48 ± 0.62 0.269
Protein 842.50 ± 247.38 839.00 ± 188.76 0.925
LDH 166.80 ± 36.71 166.50 ± 35.14 0.863
Glucose 92.15 ± 22.39 91.60 ± 19.81 0.935In group A one patient had empyema, 2 patients had mild
bleeding controlled by hemostatics, 2 patients had hydropneu-




Pleural eﬀusion Ascetic ﬂuid
7.58 ± 0.31 7.65 ± 0.32 0.399
861.00 ± 157.93 1595.00 ± 2151.99 0.317
169.00 ± 36.35 174.00 ± 41.42 0.544
94.30 ± 12.20 93.50 ± 21.99 0.871






No. % No. %
Empyema 1 5 1 10 0.268 0.605
Mild bleeding 2 10 3 30 1.920 0.166
SC emphysema 2 10 3 30 1.920 0.166
Hydropneumothorax 2 10 0 0 1.071 0.301
Encephalopathy 1 5 3 30 3.606 0.058
Mortality 0 0 0 0 – –
Figure 1 Pleural effusion before procedure.
Figure 2 Drained effusion with small bore catheter.
Figure 3 Successful pleurodesis after 1 month.
190 A.A. Hewidy et al.gical emphysema that was resolved with oxygen therapy and
one patient had hepatic encephalopathy that improved with
medical treatment and there was no procedure related
mortality. In group B one patient had empyema, 3 patients
had mild bleeding controlled by hemostatics, 3 patients had
surgical emphysema that was resolved with oxygen therapy
and 3 patients had hepatic encephalopathy that improved
with medical treatment and there was no procedure related
mortality (Figs. 1–3).Discussion
The patients with advanced liver cirrhosis with unilateral
pleural effusion, mostly in the right side, usually presented
with shortness of breath, cough, hypoxemia and/or chest dis-
comfort. Relief of symptoms and prevention of pulmonary
complications and infections are critical for the patients with
refractory hepatic hydrothorax [6].
Conventional treatment methods for hepatic hydrothorax
such as sodium restriction and diuretics, and repeated thora-
centesis cannot give the treatment target in many patients.
Increasing the doses of diuretics to achieve the negative sodium
balance may precipitate hepatic encephalopathy and may
increase the serum creatinine level, which indicates a decrease
in the glomerular ﬁltration rate. Although, thoracentesis for
hepatic hydrothorax is both useful and safe, thoracentesis
dependence may be associated with deteriorating clinical status
and impaired quality of life. Actually, when thoracentesis is
required every 2–3 weeks, alternative strategies must be con-
sidered [9].
The term refractory hepatic hydrothorax is used when med-
ical treatment with salt restriction and diuretics are ineffective,
as prolonged diuretic treatment may result in depletion of the
intravascular volume and impaired renal function. Many
authors also consider that clinical management of hepatic
hydrothorax is usually difﬁcult and ineffective and can result
in deterioration of the clinical status There have been a variety
of mechanisms to explain the shift of ascitic ﬂuid into the pleu-
ral space, including hypoalbuminemia, azygos vein hyperten-
sion, leakage from the thoracic duct, transdiaphragmatic
lymphatic migration and most important, the pressure –
gradient – directed ﬂow through diaphragmatic defects [5].
Pleural drainage by chest tube thoracostomy can be very
dangerous in patients with massive ascites and pleural effusion.
Runyon et al. [10] reported two deaths resulting from
associated massive electrolyte and protein depletion. Also,
prolonged drainage through the chest tube may cause renal
failure, impaired immunological functions and iatrogenic
infection as common complications [11].
Pleural drainage by chest tube thoracostomy and chemical
pleurodesis was attempted by using tetracycline in 1977 by
Falchuk et al. [12].
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effusion and ascites with no signiﬁcant difference between bio-
chemical analysis of both ascetic ﬂuid and pleural ﬂuid, direct
Gram stain of ascitic ﬂuid and pleural effusion in both groups
showed no organisms, ZN stain for all patients was negative
and the cytopathological examination was free from malignant
cells.
There was statistically signiﬁcant difference in group A in
improvement of dyspnea, dry cough and productive cough
after pleurodesis and in group B there was statistically signiﬁ-
cant difference in improvement of dyspnea after pleurodesis.
In group A, 13 patients (65%) had successful pleurodesis
and 7 patients (35%) had recurrent effusion after 1 month.
In group B, 7 patients (70%) had successful pleurodesis and
3 patients (30%) had recurrent effusion after 1 month. These
results were comparable to those reported by Woo et al. [6]
who used Viscum album and found that refractory hepatic
hydrothorax can be controlled with chemical pleurodesis via
chest tube with or without VATS in as many as 72.7% of
patients. It is also comparable to those reported by Kaddah
et al. [13] who revealed that chemical pleurodesis was effective
in the treatment of hepatic hydrothorax in 15/20 patients
(75%), there were 7/8 cases (87.5%) treated by bovoiodine,
4/6 cases (66.7%) with vibramycin and 4/6 cases (66.7%) with
talc slurry. The success rate in patients subjected to Viscum
pleurodesis was less than that obtained by El-Morsy et al.
[14] (87.9%) who used SBC in malignant pleural effusion
and this is accepted as the success rate in malignant effusion
was more than that in hepatic hydrothorax.
The duration of hospital stay was 10.05 ± 2.48 days in group
A and 11.70 ± 2.36 days in group B which was not statistically
signiﬁcant. This was comparable to Kaddah et al. [13] in which
the time needed to remove the chest tube was 9.8 ± 2.3 days,
but it was more than that reported by El-Morsy et al. [14] pleu-
rodesis via SBC (6.5 days) regardless the agent used and it can
be explained as they used it malignant pleural effusion.
Post procedure chest pain score showed that in group A 5
patients (25%) had no chest pain, 13 patients (65%) had mild
pain and did not need any analgesia, one patient had discom-
forting pain that improved by mild analgesia paracetamol
500 mg tablet and one patient had distressing pain and needed
strong analgesia (Ketorolac injection). In group B one patient
(10%) had no chest pain, 3 patients (30%) had mild pain and
did not need any analgesia, 4 patient (40%) had discomforting
pain that improved by mild analgesia paracetamol 500 mg
tablet and 2 patients had distressing pain and needed strong
analgesia (Ketorolac injection). Post procedure chest pain
score was less in group A than in group B which was statisti-
cally signiﬁcant so that small bore catheter pleurodesis is more
comfortable to the patients than large bore catheter.
In group A one patient had empyema, 2 patients had mild
bleeding controlled by hemostatics, 2 patients had hydropneu-
mothorax and resolved spontaneously, 2 patients had surgical
emphysema that resolved with oxygen therapy and one patient
had hepatic encephalopathy that improved with medical
treatment and there was no procedure related mortality, in
group B one patient had empyema, 3 patients had mild bleeding
controlled by hemostatics, 3 patients had surgical emphysema
that resolved with oxygen therapy and 3 patients had hepatic
encephalopathy that improved with medical treatment and
there was no procedure related. These complications were
less than those reported by Woo et al. [6] who reportedcomplications occurred were low grade fever/leukocytosis
(100.0%), pneumonia (9.1%), pneumothorax (36.4%), azote-
mia/acute renal failure (54.6%) and hepatic encephalopathy
(36.4%). Chest pain and percutaneous drainage (PCD) site pain
and chest pain occurred in all the 11 patients during the chemical
pleurodesis. Five patients (45.5%) were suspected to have
procedure-relatedmortality due to the occurrence of acute renal
failure. This difference was due to good selection of our patients
and less invasive procedures in our study. Our results were com-
parable to those of Kaddah et al. [13] who showed that 7 out of
the 22 cases reported absence of any complications. The remain-
ing cases (15 patients) showed early and mostly minimal and
limited morbidity. There were 4/22 patients (18.2%) suffering
from surgical emphysema, 2 cases (9.1%) with minimal left side
pleural effusion, 2 cases (9.1%) with superﬁcial wound infec-
tion, one case (4.5%) with mild thoracic pain and a single case
(4.5%) developed prehepatic coma 4 days after the procedure,
who was cured by medical therapy and had no recurrence of
hepatic hydrothorax.Conclusion
Small bore catheter chemical pleurodesis is not inferior to large
bore tube chemical pleurodesis in management of refractory
hepatic hydrothorax with successful outcome, less post proce-
dure chest pain and minimal complications.Conflict of interest
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